Primary cutaneous blastic plasmacytoid dendritic cell neoplasm without extracutaneous manifestation: Case report and review of the literature

Pathology Research and Practice

Volumn 207, Issue 1, 2011, Pages 55-59

  Li, Yang ^a   Li, Zhi ^a   Lin, Han liang ^a   Chen, Xiao hong ^a   Li, Bin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Blastic NK cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; CD4+ CD56+ hematodermic neoplasm

Indexed keywords

CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ADULT; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; BLOOD EXAMINATION; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CELL INFILTRATION; DERMIS; DISEASE COURSE; DRUG RESPONSE; ERYTHEMA; FOLLOW UP; HEAD; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LIMB; MALE; MULTIPLE CYCLE TREATMENT; PROGNOSIS; SKIN BIOPSY; SKIN DEFECT; SKIN NODULE; SUBCUTANEOUS TISSUE; TRUNK; TUMOR CELL;

ADULT; ANTIGENS, CD4; ANTIGENS, CD56; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; DEXAMETHASONE; DIAGNOSIS, DIFFERENTIAL; DOXORUBICIN; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, CUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; SKIN; SKIN NEOPLASMS; TREATMENT OUTCOME; VINCRISTINE;

EID: 78650238527     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.05.008     Document Type: Article

References (17)

1. Jaye D.L., Geigerman C.M., Herling M., Eastburn K., Waller E.K., Jones D. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod. Pathol. 2006, 19:1555-1562.
2. Facchetti F., Jones D.M., Petrella T. Blastic plasmacytoid dendritic cell neoplasm. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 145-147. IARC Press, Lyon. fourth ed. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
3. Feuillard J., Jacob M.C., Valensi F., Maynadie M., Gressin R., Chaperot L., Arnoulet C., Brignole-Baudouin F., Drenou B., Duchayne E., Falkenrodt A., Garand R., Homolle E., Husson B., Kuhlein E., Le Calvez G., Sainty D., Sotto M.F., Trimoreau F., Bene M.C. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002, 99:1556-1563.
4. Weaver J., Hsi E.D. CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma). J. Cutan. Pathol. 2008, 35:975-977.
5. Chan J.K.C., Jasse E.S., Ralfkiaer E. Blastic NK-cell lymphoma. World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues 2001, 214-215. IARC Press, Lyon. E.S. Jaffe, N.L. Harris, H. Stein (Eds.).
6. Shinoda K., Muraki T., Yano M., Yamada T., Takao A. Infant leukemia suggestive of natural killer cell precursor origin followed an unusual clinical course. Acta Haematol. 2000, 104:202-206.
7. Adachi M., Maeda K., Takekawa M., Hinoda Y., Imai K., Sugiyama S., Yachi A. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am. J. Hematol. 1994, 47:278-282.
8. Bekkenk M.W., Jansen P.M., Meijer C.J., Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann. Oncol. 2004, 15:1097-1108.
9. Yamada O., Ichikawa M., Okamoto T., Park C., Motoji T., Mizoguchi H., Shibuya A. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. Br. J. Haematol. 2001, 113:153-160.
10. Reimer P., Rudiger T., Kraemer D., Kunzmann V., Weissinger F., Zettl A., Konrad Müller-Hermelink H., Wilhelm M. What is CD4+CD56+ malignancy and how should it be treated?. Bone Marrow Transplant. 2003, 32:637-646.
11. Dijkman R., van Doorn R., Szuhai K., Willemze R., Vermeer M.H., Tensen C.P. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007, 109:1720-1727.
12. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., Ralfkiaer E., Chimenti S., Diaz-Perez J.L., Duncan L.M., Grange F., Harris N.L., Kempf W., Kerl H., Kurrer M., Knobler R., Pimpinelli N., Sander C., Santucci M., Sterry W., Vermeer M.H., Wechsler J., Whittaker S., Meijer C.J. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
13. Marafioti T., Paterson J.C., Ballabio E., Reichard K.K., Tedoldi S., Hollowood K., Dictor M., Hansmann M.L., Pileri S.A., Dyer M.J., Sozzani S., Dikic I., Shaw A.S., Petrella T., Stein H., Isaacson P.G., Facchetti F., Mason D.Y. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood 2008, 111:3778-3792.
14. Petrella T., Meijer C.J., Dalac S., Willemze R., Maynadie M., Machet L., Casasnovas O., Vergier B., Teitell M.A. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am. J. Clin. Pathol. 2004, 122:307-313.
15. Petrella T., Comeau M.R., Maynadi M., Couillault G., De Muret A., Maliszewski C.R., Dalac S., Durlach A., Galibert L. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am. J. Surg. Pathol. 2002, 26:852-862.
16. Petrella T., Dalac S., Maynadie M., Mugneret F., Thomine E., Courville P., Joly P., Lenormand B., Arnould L., Wechsler J., Bagot M., Rieux C., Bosq J., Avril M.F., Bernheim A., Molina T., Devidas A., Delfau-Larue M.H., Gaulard P., Lambert D. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am. J. Surg. Pathol. 1999, 23:137-146.
17. Petrella T., Bagot M., Willemze R., Beylot-Barry M., Vergier B., Delaunay M., Meijer C.J., Courville P., Joly P., Grange F., De Muret A., Machet L., Dompmartin A., Bosq J., Durlach A., Bernard P., Dalac S., Dechelotte P., D'Incan M., Wechsler J., Teitell M.A. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am. J. Clin. Pathol. 2005, 123:662-675.